IMNM (Immunome) Quality Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IMNM Immunome Inc IMNM
44 GF Score
Price $22.32
GF Value $1.70
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Immunome Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Immunome Quality Rank Related Terms

IMNM
44GF Score
Immunome Inc IMNM
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Immunome (IMNM) Overvalued in 2026?

Based on GuruFocus' analysis, Immunome stock appears to be overvalued. The current stock price of $22.32 is trading 1212.9% above its estimated GF Value™ of $1.70. GuruFocus considers Immunome to be Significantly Overvalued.

Key valuation signals for IMNM:

  • Quality Rank:
  • GF Value™: $1.70 vs. price of $22.32 (1212.9% above fair value)
  • GF Score™: 44/100 with 2 warning signs

No single metric tells the full story. See the IMNM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Immunome Business Description

Address 18702 N. Creek Parkway, Suite 100, Bothell, WA, USA, 98011
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.
44GF Score

Get the complete analysis for IMNM

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$22.32
Price
$1.70
GF Value